PharmaVoice

JUNE 15, 2022

Eledon Pharmaceuticals’ grassroots-backed drug recently entered clinical trials.

264

264

pharmaphorum

JUNE 15, 2022

The 2nd NSCLC Drug Development Summit returns for its second year to unite biopharma and academic leaders during an exciting era of personalized medicine. The industry is uniting to address mechanisms of drug resistance, spearhead progress in molecular subtyping and define practice-changing drug sequencing and combinations for the largest solid tumor indication, NSCLC.

Immunization 105

Immunization 105

Board Vitals - Pharmacist

JUNE 15, 2022

Physicians aren’t alone in their continuing education requirements. Nursing continuing education is required in most states to ensure that nurses and nurse practitioners keep their knowledge up to date. What do you need to know about CME for nurses, and how can you fulfill your requirements? . Why Do Nurses Need to Earn Continuing Education? . As the medical industry advances, so must the knowledge nurses have.

52

52

pharmaphorum

JUNE 15, 2022

Astellas’ oral HIF-PH inhibitor Evrenzo has become the first drug in the class to be recommended for routine NHS use as a treatment for anaemia in chronic kidney disease (CKD), ahead of rivals from Otsuka and GlaxoSmithKline. The decision by cost-effectiveness watchdog NICE means that Evrenzo (roxadustat) is the first oral alternative to treatment with injectable iron supplements or erythropoietin-based therapies symptomatic anaemia associated with CKD.

Hospitals 59

Hospitals FDA 59

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Patient Care

Compounding Pharmacy of America

JUNE 15, 2022

A single bad night’s sleep is common once in a while, but it should not be the norm. If you have a hard time sleeping more than a few times a week, whether that’s getting to sleep or staying asleep, be sure to seek medical help. The post How to Get Better Sleep Throughout the Night appeared first on The Compounding Pharmacy of America.

Compounding Pharmacies 52

Compounding Pharmacies Compounding 52

NICE

JUNE 15, 2022

By Jeanette Kusel, director of scientific advice, Mark Salmon, programme director of information resrouces and Sarah Byron, interim programme director for devices, diagnostics and digital at NICE. The explosion in digital health products has left NHS commissioners wondering how they can possibly sift out what works and what provides maximum benefit for the service and for patients.

52

52

NICE

JUNE 15, 2022

I’ve seen many changes to the health and care landscape since I’ve been at NICE – some more significant than others. But I feel that the point we’re at now is particularly striking. New, innovative, and potentially disruptive treatments are being developed at a pace we haven’t seen before – leading to medicines of great range and complexity.

52

52

PharmExec

JUNE 15, 2022

Larger pipeline and increased support from regulatory authorities are setting up the orphan drug market for long-term success.

52

52

NICE

JUNE 15, 2022

Innovative medicines, medical devices and diagnostics are arriving at an unprecedented pace. At NICE, it’s our duty to keep ahead of these developments to make sure patients gain rapid access to the most promising, cutting-edge treatments. So, we’re taking a number of measures to address this. These include developing a proportionate approach to technology appraisals to increase our capacity.

52

52

Outsourcing Pharma

JUNE 15, 2022

Unveiled at the 2022 BIO International Convention, the group's third annual diversity, equity, and inclusion report spotlights improvements both made and needed.

52

52

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

pharmaphorum

JUNE 15, 2022

Over the last half-decade, we have witnessed game-changing developments within the cannabinoid field, driving it into a new era of rigorous research, promising clinical trials and multimillion-dollar deals. The 5 th International Cannabinoid-Derived Pharmaceuticals Summit brings together drug developers working on the complex production of both plant-based, biosynthetic and synthetic endocannabinoid system modulators.

52

52

Pharma Times

JUNE 15, 2022

Jazz Pharmaceuticals and Redx announce that pan-RAF inhibitor will enter clinical development

49

49

Med Ed 101

JUNE 15, 2022

Converting Risperidone to Other Antipsychotics Lifelong antipsychotic therapy is often needed to adequately manage psychiatric conditions. Unfortunately, therapy often needs to be adjusted to optimize efficacy while avoiding undesirable side effects. Risperidone (Risperdal) is a second-generation antipsychotic (SGA) commonly used in practice but tends to have a higher risk of producing certain adverse effects compared […].

40

40

Pharma Times

JUNE 15, 2022

The deal will boost CatSci’s ability to deliver best-in-class medicines to patients worldwide

49

49

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

FDA

Pharma Manufacturing

JUNE 15, 2022

Three priorities for re-strategizing digital transformation post-COVID

40

40

Pharmaceutical Commerce

JUNE 15, 2022

CDMO’s Ireland campus will increase in capacity by 50% as a result.

40

40

pharmaphorum

JUNE 15, 2022

Tech startup Proximie has raised $80 million in third-round financing that will be used to further develop its augmented reality platform, which allows surgeons to share best practices with other clinicians anywhere in the world. The London, UK-based company’s connected operating room (OR) platform means doctors can physically show each other where to make an incision – in real-time – or use physical gestures to illustrate a technique.

Hospitals 98

Hospitals Patient Care 98

Pharmaceutical Commerce

JUNE 15, 2022

Focus on operational excellence is playing a major role in this effort, company says.

40

40

Advertisement

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

Pharmacy Management Software

pharmaphorum

JUNE 15, 2022

Boehringer Ingelheim must like what it has seen in its two-year-old R&D collaboration with Trutino Biosciences to develop cytokine therapies – it has just taken an option to buy the company outright. The German pharma group originally teamed up with San Diego-based Trutino on a project to apply its drug discovery and development platform to three undisclosed cytokines, making them safer and potentially more effective as treatments for cancer as they could be administered at higher doses.

Immunization 98

Immunization Vaccines 98

pharmaphorum

JUNE 15, 2022

Manufacturing problems wreaked havoc with Mallinckrodt’s first attempt to secure FDA approval of its treatment candidate terlipressin for hepatorenal syndrome (HRS), but the drugmaker is having another attempt. The Dublin, Ireland-headquartered company said the resubmission will allow more time for the FDA to inspect a packaging and labelling manufacturing facility for the drug, which as a result of a COVOD-19 backlog could not be completed before its deadline to review the original applic

FDA 59

FDA Packaging Labelling 59